Aurinia Pharmaceuticals  logo
Aurinia Pharmaceuticals AUPH
$ 16.12 1.5%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

Aurinia Pharmaceuticals Cash Flow 2025-2011 | AUPH

Brief cash flow overview of Aurinia Pharmaceuticals

The comparison covers five available annual reports between 2021 and 2025.

Operating cash flow reversed from -$157.7 million to $135.7 million, improving the company's ability to fund itself.

Operating cash flow was positive in only 2 of five periods. Cash generation remains unstable.

Receivables and inventory net of payables grew by $53 million, absorbing resources equal to about 68.7% of revenue.

Cash flow takeaway

Aurinia Pharmaceuticals 's profile is moderate, with strengths in cash generation offset by factors that constrain free cash.

Annual Cash Flow Aurinia Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

136 M 44.4 M -33.5 M -79.5 M -158 M -69.9 M -63.6 M -51.6 M - - - - - - -

Depreciation & Amortization

19.4 M 19.4 M 11.6 M 2.71 M 2.76 M 1.37 M 33 K 20 K - - - - - - -

Accounts Payables

3.31 M 5.19 M 4.33 M 3.09 M 3.88 M 2.64 M - - - - - - - - -

Accounts Receivables

41.5 M 36.5 M 24.1 M 13.5 M 15.4 M 1.02 M - - - - - - - - -

Total Inventories

45.7 M 39.2 M 39.7 M 24.8 M 19.3 M 13.9 M - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Aurinia Pharmaceuticals

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

85.1 M 32.6 M - - 1.3 M - - - -18.6 M - - - -31.7 M - -90 M - -46.7 M - -132 M - -53.5 M - -73.1 M -44.6 M -22.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

9.65 M 4.82 M 200 K 200 K 4.86 M - 200 K 200 K 4.85 M - 500 K 500 K 717 K - 500 K 500 K 687 K - 2.03 M 200 K 688 K - - - 12 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

1.74 M 2.66 M 2.21 M 3.31 M 4.22 M 5.19 M 8.88 M 8.42 M 5.67 M 4.33 M 8.85 M 4.81 M 3.68 M 3.09 M - - 3.27 M 3.88 M 3.26 M 2.54 M 2.18 M 2.64 M 2.64 M 2.64 M 2.64 M 4.15 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

41.1 M 49.2 M 30.7 M 40.1 M 40.4 M 36.5 M 36.5 M 25.5 M 28.9 M 24.1 M 37.9 M 19.5 M 19 M 13.5 M 41.8 M - 20.4 M 15.4 M 9.81 M 4.42 M 1.19 M - - - - 368 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

45.2 M 46.4 M 44.8 M 46.5 M 46.2 M 39.2 M 38.7 M 38.9 M 39.8 M 39.7 M 32.8 M 33.2 M 31.7 M 24.8 M 25.3 M - 26.3 M 19.3 M 19.3 M 17.4 M 15.9 M 13.9 M 13.9 M 13.9 M 13.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Aurinia Pharmaceuticals , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Codexis Codexis
CDXS
$ 1.42 0.33 % $ 124 M usaUSA
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cue Biopharma Cue Biopharma
CUE
$ 27.67 2.63 % $ 2.62 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Editas Medicine Editas Medicine
EDIT
$ 3.08 0.33 % $ 273 M usaUSA
Ardelyx Ardelyx
ARDX
$ 3.71 1.06 % $ 894 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
$ 4.57 0.21 % $ 335 K usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.66 0.04 % $ 3.01 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 36.13 4.38 % $ 405 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
$ 2.42 0.61 % $ 287 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 6.66 5.38 % $ 4.45 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.71 0.04 % $ 75.6 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.0 2.08 % $ 301 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 208.35 0.16 % $ 10.4 B usaUSA
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 57.46 2.9 % $ 1.65 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 66.43 0.04 % $ 12.7 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands